Information Collection

Studies to Enhance FDA Communications Addressing Biosimilar Drug Products: Focus Groups with Patients

IC 236377 under ICR 201712-0910-001 · OMB 0910-0695.

Documents and Forms

Documents and forms in this information collection
Document NameDocument Type
Split Web and Phone Screener.docx Other-Split Web and Phone Screener
Consent Form.docx Other-Consent Form
Screener Invitation Email.docx Other-Invitation Email
Confirmation Email.docx Other-Confirmation Email
Moderator Guide.docx Other-Moderator Guide
InterVu Respondent Invitation Template.docx Other-InterVu Respondent Invitation
0695 OMB Approval Memo for Addressing Biosimilar Drug Product 2019.docx
OMB approval memo
IC Document

Information Collection (IC) Details

View Information Collection (IC)

layout table

Information Collection Instruments:
table that charts list of instruments
Document Type Form No. Form Name Instrument File URL Available Electronically? Can Be Submitted Electronically? Electronic Capability
Other-Split Web and Phone Screener Yes Yes Fillable Fileable
Other-Consent Form Yes Yes Fillable Fileable
Other-Invitation Email Yes No Printable Only
Other-Confirmation Email Yes No Printable Only
Other-Moderator Guide Yes No Printable Only
Other-InterVu Respondent Invitation Template Yes No Printable Only

Federal Enterprise Architecture Business Reference Module


table that charts list of burden
  Approved Program Change Due to New Statute Program Change Due to Agency Discretion Change Due to Adjustment in Agency Estimate Change Due to Potential Violation of the PRA Previously Approved
Annual Number of Responses for this IC 1,000 0 1,000 0 0 0
Annual IC Time Burden (Hours) 192 0 192 0 0 0
Annual IC Cost Burden (Dollars) 0 0 0 0 0 0

Documents for IC
table that charts IC Documents
Title Document Date Uploaded
OMB approval memo 06/17/2019
            Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.
Something went wrong when downloading this file. If you have any questions, please send an email to [email protected].